AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Splicing factor 3B subunit 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15427

UPID:

SF3B4_HUMAN

Alternative names:

Pre-mRNA-splicing factor SF3b 49 kDa subunit; Spliceosome-associated protein 49

Alternative UPACC:

Q15427; Q5SZ63

Background:

Splicing factor 3B subunit 4 (SF3B4), also known as Pre-mRNA-splicing factor SF3b 49 kDa subunit or Spliceosome-associated protein 49, plays a crucial role in pre-mRNA splicing. It is a component of the SF3B complex, essential for the 'A' complex assembly and U2 snRNP's stable binding to the branchpoint sequence in pre-mRNA. SF3B4's involvement extends to the assembly of the 'E' complex and the splicing of U12-type introns, highlighting its multifaceted role in RNA processing.

Therapeutic significance:

SF3B4's mutation is linked to Acrofacial dysostosis 1, Nager type, characterized by craniofacial and limb malformations. Understanding the role of SF3B4 could open doors to potential therapeutic strategies for this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.